Centene Corp receives A+ valuation grade amid strong healthcare sector outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2024
0mins
Source: SeekingAlpha
Centene Corp's stock rose 5.41% and reached a 52-week high despite the Nasdaq-100 declining 1.48% and the S&P 500 down 0.19%.
The company received an A+ valuation grade from Seeking Alpha, highlighting its competitive positioning among U.S. healthcare stocks. This strong valuation, along with the ongoing growth in healthcare services and pharmaceuticals, is attracting investor interest, indicating potential for substantial returns in future investments.
As the healthcare sector continues to grow, Centene's strong valuation metrics may lead to increased capital inflow, further enhancing its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNC
Wall Street analysts forecast CNC stock price to fall
15 Analyst Rating
5 Buy
8 Hold
2 Sell
Hold
Current: 62.700
Low
32.00
Averages
43.07
High
59.00
Current: 62.700
Low
32.00
Averages
43.07
High
59.00
About CNC
Centene Corporation is a healthcare company. It provides access to quality healthcare; programs and a range of health solutions that help families and individuals get well. Its segments include Medicaid, Medicare, Commercial and Other. The Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surge in Options Trading for Healthcare Stocks
- Healthcare Stocks Surge: On Thursday, healthcare stocks outperformed as the broader market rose, with insurers Humana and Centene hitting new highs and UnitedHealth Group nearing its one-year peak, indicating a strong recovery in the sector and increased investor confidence.
- Active Options Trading: The State Street Health Care Select Sector SPDR ETF (XLV) saw 5,300 call options traded on Thursday, significantly outpacing just over 1,000 puts, reflecting bullish sentiment and expectations for future growth in the healthcare industry.
- Eli Lilly Leads Gains: Eli Lilly's stock rose over 4% towards all-time highs, with call options outnumbering puts more than two-to-one, showcasing strong demand for its weight loss drugs and confidence in future profitability.
- Comparative Financial Sector Performance: In contrast to the robust performance of healthcare stocks, options trading in the financial sector appeared muted, with nearly 380,000 options traded in the State Street Financial Select Sector ETF (XLF), indicating a more cautious market outlook for financials.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Mixed US Stock Market with Tech Stocks Under Pressure
- Tech Stock Decline: Broadcom (AVGO) shares plummeted over 15% after its AI revenue forecast fell short, marking it as the largest decliner in the Nasdaq 100, which reflects growing concerns about the tech sector and may dampen investor confidence.
- Weak Employment Data: Initial jobless claims in the US rose by 13,000 to 225,000, reaching a 3.75-month high, indicating a weakening labor market that could lead to downward revisions in growth expectations.
- Healthcare Stocks Strong: UnitedHealth Group (UNH) surged over 6%, leading gains in the S&P 500, after Bank of America upgraded its rating from neutral to buy with a price target of $450, showcasing resilience in the healthcare sector.
- International Market Volatility: European markets showed mixed results, with Eurozone April retail sales falling 0.4% month-over-month, worse than the expected 0.3%, indicating weak consumer spending that could pressure future economic growth.
See More
Valuation Analysis of U.S. Healthcare Stocks
- Valuation Overview: Seeking Alpha's valuation grades highlight companies like Centene Corporation (CNC) and Pfizer (PFE) as attractive investment options among U.S. healthcare stocks with market caps over $10 billion, indicating their competitive positioning in the sector.
- Strong Valuation Metrics: Centene Corporation received an A+ valuation grade, while Pfizer earned an A, and BioMarin Pharmaceutical and Bristol-Myers Squibb received A- and A grades respectively, suggesting these companies are relatively undervalued in the market, potentially attracting investor interest.
- Comprehensive Assessment Method: The valuation grades are based on various financial metrics, including P/E, PEG, and EV/Sales ratios, factoring in both current and forward estimates to ensure investors have a holistic view of the companies' financial health.
- Healthcare Sector Outlook: With the ongoing growth in healthcare equipment, services, and pharmaceuticals, these high-rated stocks not only reflect current market value but may also provide substantial returns in future investments, drawing more capital into the sector.
See More
Morgan Stanley Bullish on Dividend Stocks
- Dividend Potential Analysis: Morgan Stanley highlights that companies initiating dividends outperform the market by an average of 650 basis points in the six months following the announcement and by 1,000 basis points in the subsequent 12 months, indicating a significant enhancement in investor returns, especially when dividends are reinvested for compounding benefits.
- Centene's Advantages: Centene boasts an 18% free cash flow yield and a net cash position exceeding 5% of its market cap, making it an ideal candidate for dividends; additionally, the company surpassed expectations for adjusted earnings per share and revenue in Q1, with its stock rising 44% this year.
- BioMarin's Acquisition Impact: BioMarin, with a net cash position of 7.6% of its market cap and a 10.4% free cash flow yield, successfully made the list after completing a $4.8 billion acquisition of Amicus Therapeutics, which is expected to significantly enhance its market share in rare metabolic diseases, although it slightly lowered its 2026 non-GAAP earnings per share guidance while raising its full-year revenue guidance to $3.825 to $3.925 billion.
- Deckers Outdoor's Growth Outlook: Deckers Outdoor posted better-than-expected results for its fiscal Q1, with a free cash flow yield of 6.7%, and analysts have rated the stock as a buy, anticipating that its portfolio of category-defining brands will drive future growth, with shares gaining nearly 10% this year.
See More
Surge in Options Trading for Healthcare Stocks
- Healthcare Stocks Surge: On Thursday, healthcare stocks outperformed as the broader market rose, with insurers Humana and Centene hitting new highs and UnitedHealth Group nearing its one-year peak, indicating a strong recovery in the sector and increased investor confidence.
- Active Options Trading: The State Street Health Care Select Sector SPDR ETF (XLV) saw 5,300 call options traded on Thursday, significantly outpacing just over 1,000 puts, reflecting bullish sentiment and expectations for future growth in the healthcare industry.
- Eli Lilly Leads Gains: Eli Lilly's stock rose over 4% towards all-time highs, with call options outnumbering puts more than two-to-one, showcasing strong demand for its weight loss drugs and confidence in future profitability.
- Comparative Financial Sector Performance: In contrast to the robust performance of healthcare stocks, options trading in the financial sector appeared muted, with nearly 380,000 options traded in the State Street Financial Select Sector ETF (XLF), indicating a more cautious market outlook for financials.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Mixed US Stock Market with Tech Stocks Under Pressure
- Tech Stock Decline: Broadcom (AVGO) shares plummeted over 15% after its AI revenue forecast fell short, marking it as the largest decliner in the Nasdaq 100, which reflects growing concerns about the tech sector and may dampen investor confidence.
- Weak Employment Data: Initial jobless claims in the US rose by 13,000 to 225,000, reaching a 3.75-month high, indicating a weakening labor market that could lead to downward revisions in growth expectations.
- Healthcare Stocks Strong: UnitedHealth Group (UNH) surged over 6%, leading gains in the S&P 500, after Bank of America upgraded its rating from neutral to buy with a price target of $450, showcasing resilience in the healthcare sector.
- International Market Volatility: European markets showed mixed results, with Eurozone April retail sales falling 0.4% month-over-month, worse than the expected 0.3%, indicating weak consumer spending that could pressure future economic growth.
See More
Valuation Analysis of U.S. Healthcare Stocks
- Valuation Overview: Seeking Alpha's valuation grades highlight companies like Centene Corporation (CNC) and Pfizer (PFE) as attractive investment options among U.S. healthcare stocks with market caps over $10 billion, indicating their competitive positioning in the sector.
- Strong Valuation Metrics: Centene Corporation received an A+ valuation grade, while Pfizer earned an A, and BioMarin Pharmaceutical and Bristol-Myers Squibb received A- and A grades respectively, suggesting these companies are relatively undervalued in the market, potentially attracting investor interest.
- Comprehensive Assessment Method: The valuation grades are based on various financial metrics, including P/E, PEG, and EV/Sales ratios, factoring in both current and forward estimates to ensure investors have a holistic view of the companies' financial health.
- Healthcare Sector Outlook: With the ongoing growth in healthcare equipment, services, and pharmaceuticals, these high-rated stocks not only reflect current market value but may also provide substantial returns in future investments, drawing more capital into the sector.
See More
Morgan Stanley Bullish on Dividend Stocks
- Dividend Potential Analysis: Morgan Stanley highlights that companies initiating dividends outperform the market by an average of 650 basis points in the six months following the announcement and by 1,000 basis points in the subsequent 12 months, indicating a significant enhancement in investor returns, especially when dividends are reinvested for compounding benefits.
- Centene's Advantages: Centene boasts an 18% free cash flow yield and a net cash position exceeding 5% of its market cap, making it an ideal candidate for dividends; additionally, the company surpassed expectations for adjusted earnings per share and revenue in Q1, with its stock rising 44% this year.
- BioMarin's Acquisition Impact: BioMarin, with a net cash position of 7.6% of its market cap and a 10.4% free cash flow yield, successfully made the list after completing a $4.8 billion acquisition of Amicus Therapeutics, which is expected to significantly enhance its market share in rare metabolic diseases, although it slightly lowered its 2026 non-GAAP earnings per share guidance while raising its full-year revenue guidance to $3.825 to $3.925 billion.
- Deckers Outdoor's Growth Outlook: Deckers Outdoor posted better-than-expected results for its fiscal Q1, with a free cash flow yield of 6.7%, and analysts have rated the stock as a buy, anticipating that its portfolio of category-defining brands will drive future growth, with shares gaining nearly 10% this year.
See More
